Development of a prognostic nomogram model for predicting outcomes in benign esophagogastric anastomotic stenosis treated with fluoroscopic balloon dilation.

Objective: This study aims to evaluate the clinical utility and effectiveness of a nomogram model in predicting outcomes for patients with benign esophagogastric anastomotic stenosis (BES) undergoing fluoroscopic balloon dilation (FBD).

Methods: The clinical data of 428 patients with BES who received FBD treatment at our hospital between January 2013 and June 2023 were retrospectively analyzed. The patients were divided into training and validation cohorts in a 7:3 ratio.

CDK4/6 inhibitor enhances the radiosensitization of esophageal squamous cell carcinoma (ESCC) by activating autophagy signaling via the suppression of mTOR.

Objective: To investigate the radiosensitizing effect of cyclin D-cyclin dependent kinase (CDK) 4/6 inhibitor palbociclib on esophageal squamous cell carcinoma (ESCC) and its underlying mechanisms.

Methods: The effect of palbociclib on ESCC cell radiosensitivity was detected by cell counting kit-8 (CCK-8) and clonogenic assay. γH2AX immunofluorescent staining was used to assess the repair of DNA damage induced by radiation.

Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC).

Background: Recent studies have shown that according to the expression levels of achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), and POU class 2 homeobox 3 (POU2F3), small cell lung cancer (SCLC) can be divided into four subtypes: SCLC-A (ASCL1-dominant), SCLC-N (NEUROD1-dominant), SCLC-P (POU2F3-dominant), and SCLC-I (triple negative or SCLC-inflamed). However, there are limited data on the clinical characteristics and prognosis of molecular subtypes of SCLC.

Methods: Immunohistochemistry (IHC) was used to detect the expression levels of ASCL1, NEUROD1, and POU2F3 in 53 patient samples of resectable SCLC.